Antoni Ribas Selected Research

SCH772984

1/2018	Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.
8/2014	Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Antoni Ribas Research Topics

Disease

271	Melanoma (Melanoma, Malignant) 02/2024 - 11/2002
232	Neoplasms (Cancer) 02/2024 - 02/2002
28	Disease Progression 11/2023 - 01/2010
17	Neoplasm Metastasis (Metastasis) 01/2023 - 05/2007
8	Inflammation (Inflammations) 01/2022 - 05/2009
7	Diarrhea 01/2023 - 06/2007
7	Brain Neoplasms (Brain Tumor) 01/2021 - 05/2007
7	Exanthema (Rash) 01/2021 - 01/2008
7	Fever (Fevers) 01/2019 - 07/2009
7	Fatigue 01/2019 - 06/2011
6	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2024 - 06/2015
6	Prostatic Neoplasms (Prostate Cancer) 01/2023 - 08/2008
6	COVID-19 01/2022 - 11/2020
6	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2015 - 06/2011
5	Renal Cell Carcinoma (Grawitz Tumor) 11/2023 - 07/2008
4	Nausea 05/2015 - 06/2011
4	Keratoacanthoma 01/2015 - 06/2011
4	Experimental Melanoma 11/2009 - 06/2005
3	Breast Neoplasms (Breast Cancer) 06/2024 - 01/2010
3	Cytokine Release Syndrome 12/2023 - 07/2007
3	Carcinoma (Carcinomatosis) 11/2023 - 12/2005
3	Synovial Sarcoma (Synovioma) 01/2022 - 01/2017
3	Infections 01/2021 - 07/2010
3	Colorectal Neoplasms (Colorectal Cancer) 01/2021 - 08/2008
3	Leukemia 07/2019 - 11/2014
3	Pneumonia (Pneumonitis) 01/2019 - 08/2015
3	Body Weight (Weight, Body) 06/2015 - 07/2013
3	Uveal melanoma 08/2014 - 01/2012
3	Liver Neoplasms (Liver Cancer) 12/2007 - 02/2002
3	Hepatocellular Carcinoma (Hepatoma) 12/2007 - 02/2002
2	Dermatitis 06/2024 - 01/2017
2	Cardiotoxicity 12/2023 - 11/2021
2	Sarcoma (Soft Tissue Sarcoma) 01/2023 - 01/2019

Drug/Important Bio-Agent (IBA)

54	VemurafenibIBA 10/2021 - 04/2010
51	pembrolizumabIBA 01/2024 - 07/2013
45	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2024 - 01/2011
40	AntigensIBA 12/2023 - 11/2002
36	Immune Checkpoint InhibitorsIBA 02/2024 - 07/2013
35	IpilimumabIBA 10/2023 - 11/2011
31	dabrafenibIBA 01/2024 - 01/2011
27	trametinibIBA 01/2024 - 02/2013
22	AntibodiesIBA 10/2023 - 08/2006
21	Biomarkers (Surrogate Marker)IBA 12/2023 - 02/2003
20	T-Cell Antigen Receptors (T-Cell Receptor)IBA 12/2023 - 11/2009
20	Peptides (Polypeptides)IBA 01/2023 - 02/2003
20	tremelimumabIBA 01/2019 - 12/2005
18	Proteins (Proteins, Gene)FDA Link 02/2024 - 06/2003
18	RNA (Ribonucleic Acid)IBA 01/2023 - 06/2003
18	Monoclonal AntibodiesIBA 04/2016 - 12/2005
17	Neoplasm Antigens (Tumor Antigens)IBA 01/2023 - 06/2003
15	LigandsIBA 10/2022 - 08/2005
15	cobimetinibIBA 10/2021 - 08/2014
15	VaccinesIBA 01/2021 - 11/2002
13	NivolumabIBA 10/2023 - 01/2015
12	EpitopesIBA 10/2021 - 03/2003
11	CTLA-4 AntigenIBA 04/2023 - 12/2005
11	Mitogen-Activated Protein KinasesIBA 12/2020 - 01/2012
11	Dacarbazine (DIC)FDA LinkGeneric 01/2020 - 07/2007
11	HLA-A*02:01 antigenIBA 05/2013 - 03/2003
10	Phosphotransferases (Kinase)IBA 10/2022 - 08/2011
9	B7-H1 AntigenIBA 01/2023 - 06/2015
9	InterferonsIBA 01/2023 - 06/2009
8	Programmed Cell Death 1 ReceptorIBA 10/2023 - 01/2015
8	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 06/2003
8	CytokinesIBA 01/2019 - 08/2006
7	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2023 - 12/2016
6	Monophenol Monooxygenase (Tyrosinase)IBA 02/2024 - 04/2008
6	Chimeric Antigen ReceptorsIBA 02/2024 - 09/2014
6	Interferon-gamma (Interferon, gamma)IBA 02/2024 - 09/2010
6	Interleukin-2 (IL2)IBA 01/2020 - 09/2007
6	EnzymesIBA 01/2017 - 01/2009
5	Proto-Oncogene Proteins B-rafIBA 01/2016 - 09/2010
4	CateninsIBA 01/2020 - 06/2015
4	Immunoglobulin G (IgG)IBA 01/2019 - 07/2007
4	MART-1 AntigenIBA 01/2018 - 04/2008
4	Small Interfering RNA (siRNA)IBA 08/2014 - 04/2010
4	Temozolomide (Temodar)FDA LinkGeneric 02/2013 - 07/2007
3	Membrane Proteins (Integral Membrane Proteins)IBA 02/2024 - 10/2010
3	ProteomeIBA 12/2023 - 02/2015
3	Death Domain ReceptorsIBA 12/2023 - 01/2021
3	talimogene laherparepvecIBA 01/2023 - 09/2017
3	spartalizumabIBA 01/2022 - 10/2020
3	Cancer VaccinesIBA 01/2019 - 10/2007
3	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 11/2018 - 07/2012
3	PolymersIBA 01/2018 - 03/2013
3	TAK 733IBA 01/2017 - 04/2012
3	Transcription Factors (Transcription Factor)IBA 02/2015 - 01/2009
3	Dihydrotachysterol (AT 10)IBA 05/2014 - 05/2008
3	PLX 4720IBA 03/2013 - 04/2011
3	Protein Kinases (Protein Kinase)IBA 02/2013 - 04/2010
3	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 10/2011 - 02/2006
3	alpha-Fetoproteins (alpha-Fetoprotein)IBA 12/2007 - 12/2003
2	HLA-A Antigens (HLA-A)IBA 01/2023 - 01/2018

Therapy/Procedure

162	Therapeutics 01/2024 - 08/2004
96	Immunotherapy 12/2023 - 02/2002
16	Drug Therapy (Chemotherapy) 01/2018 - 01/2010
6	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2023 - 01/2014
3	Radiotherapy 06/2024 - 08/2008
3	Injections 01/2018 - 08/2004
3	Biological Therapy 11/2014 - 12/2008